We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Therapeutic plasma exchange in severe refractory autoimmune heparin‐induced thrombocytopenia with thrombosis.
- Authors
Bavli, Natalie; Christensen, Bradley; Sarode, Ravi; Hofmann, Sandra; Ibrahim, Ibrahim
- Abstract
Effective use of TPE in HIT is well described in patients with acute or subacute HIT requiring urgent cardiac bypass surgery with heparin. However, in general, fondaparinux appears to be safe and effective in HIT, with a recent systematic review of fondaparinux for HIT finding a new thrombotic event rate while receiving fondaparinux of 6-5%.9 The duration of therapy (>5 days) with heparin is a significant risk factor for HIT development. More recently, a systematic review identified 10 cases of refractory HIT treated effectively with TPE.14 The therapeutic effect of TPE in HIT is likely mediated by the removal of large intravascular anti-heparin/PF4 antibody complexes, neutrophil extracellular traps (NETs) and sufficient quantities of high-affinity heparin-independent IgG antibodies. Keywords: autoimmune heparin-induced thrombocytopenia with thrombosis; therapeutic plasma exchange; intravenous immunoglobulin EN autoimmune heparin-induced thrombocytopenia with thrombosis therapeutic plasma exchange intravenous immunoglobulin e44 e47 4 02/28/22 20220301 NES 220301 Heparin-induced thrombocytopenia (HIT) is a highly pro-thrombotic condition caused by pathogenic immunoglobulin (Ig) G against neoepitopes of platelet factor 4 (PF4)-heparin complexes.
- Subjects
PLASMA exchange (Therapeutics); IDIOPATHIC thrombocytopenic purpura; NECROSIS; THROMBOSIS; GRANULOCYTE-colony stimulating factor; PULMONARY embolism; VENOUS thrombosis
- Publication
British Journal of Haematology, 2022, Vol 196, Issue 5, pe44
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17917